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Abstract 
Objectives: Real-world evidence (RWE) is increasingly used to inform health technology 
assessments (HTAs) for resource allocation, which are valuable tools for emerging economies 
such as in  America. However, the characteristics and uses in South America are unknown. 
This study aims to identify sources, characteristics and uses of RWE in Argentina, Brazil, 
Colombia and Chile, and evaluate the context-specific challenges. The implications for future 
regulation and responsible management of RWE in the region are also considered. 
Methods: A systematic literature review, database mapping, and targeted grey literature 
search were conducted to identify the sources and characteristics of RWE. Findings were 
validated by key opinion leaders attending workshops in four South American countries. 
Results: A database mapping exercise revealed 407 unique databases. Geographic scope, 
database type, population and outcomes captured were reported. Characteristics of National 
Health Information Systems show efforts to collect interoperable data from service providers, 
insurers and government agencies, but that initiatives are hampered by fragmentation, lack of 
stewardship and resources. RWE is mainly used in South America for pharmacovigilance and 
as pure academic research, but less so for HTA decision-making or pricing negotiations and 
not at all to inform early access schemes.  
Conclusions: The quality of data collected in real-world in the case-study countries varies 
and RWE is not consistently used in healthcare decision-making. Authors recommend that 
future studies monitor the impact of digitalisation, and the potential effects of access to RWE 
on the quality of patient care.   
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Highlights 
 
Through collecting case studies from four South-American countries, this study found that  
the collection and uses of Real World Evidence (RWE) in healthcare decision making is 
inconsistent across regions, providers and insurance schemes. RWE initiatives are somewhat 
hampered by fragmentation, lack of stewardship and limited resources. 
A literature review and database mapping revealed that RWE is mainly used in South 
America for pharmacovigilance and academic research, less so for HTA decision-making or 
pricing negotiations, and not at all to inform early access schemes. 
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1. ,QWURGXFWLRQ 
Healthcare decision-makers, the pharmaceutical industry, patients and clinicians are 
LQFUHDVLQJO\ XVLQJ ³UHDO-ZRUOG´ GDWD WR DVVHVV WKH VDIHW\, effectiveness and costs of 
interventions 1,2. Real-world data (RWD) refers to health care delivery data that is routinely 
FROOHFWHG IURPVRXUFHV VXFKDVSURYLGHUV¶ paper or electronic health records (EHRs), billing 
data, clinical registries, surveys and surveillance data from health care activity 2. Real world 
evidence (RWE) is derived from the analysis of RWD and refers to the clinical evidence of a 
PHGLFDO SURGXFW¶V EHQHILWV DQG ULVNV VDIHW\ DQG HIIHFWLYHQHVV 2. It is used globally to 
complement data from randomized controlled trials (RCTs), for example when assessing the 
cost-effectiveness and safety of interventions in clinical practice, enabling the generalization 
of clinical findings to a more inclusive and larger population 1. 
It has long been recognised that evidence from RCTs is insufficient when used as the sole 
basis for coverage or decision-making in healthcare 1,3. While clinical efficacy can be 
demonstrated using RCTs, required length of trials, the exclusion of major population 
subgroups and its costs renders them controversial as the only basis of evidence for health 
technology assessments (HTAs) 1,4. To complement RCT data, regulators such as the Food 
and Drug Administration (FDA) in the United States (US) and the European Medicines 
Agency (EMA) have been gradually incorporating the use of RWE to assess the value of new 
interventions and monitor their safety and effectiveness following approval for clinical use 2,5-
7
. This is often a condition to early authorisation or fast-track approval of treatments that fulfil 
major unmet medical needs, key public health issues or, rare diseases 8. The healthcare sector 
is increasingly willing to accept less certainty in treatment effectiveness in return for fast 
patient access to innovative treatments 8,9. In return for initial licensing for a specific patient 
population based on limited clinical data, research institutions and pharmaceutical companies 
are becoming more advanced in mining data to monitor and evaluate the safety and 
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effectiveness of their interventions to reduce uncertainty in the post-marketing authorization 
phase 9. 
In contrast, emerging economies rarely capture transferrable and reliable RWE that can be 
used by regulators or for HTA decision-making. Regions such as Latin America, Asia Pacific 
and Africa tend to have significant unmet medical needs, major public health issues and 
populations with a high burden of communicable and chronic diseases. This might lead to 
potential health outcome benefits and cost-savings derived from the introduction of RWE to 
inform resource allocation and fast-tracked regulatory and coverage decisions.  
The healthcare sector in Latin America is transforming. In recent years, the region has 
recorded an increase in healthcare spending 10, expanded health coverage and launched 
several successful public health initiatives across the region 11. While there is an increasing 
aging population and the region is experiencing an epidemiological shift from infectious to 
chronic diseases, health outcomes and life expectancies are improving dramatically 12,13. HTA 
agencies and regulations have emerged across the Latin American countries to contain the 
increasing costs of public healthcare by improving the allocation of limited resources. 
However, reliable and robust sources for RWE are few, so local decision makers are reluctant 
to tolerate the risk of selection bias, uncontrolled confounding and endogeneity derived from 
unreliable RWD. Furthermore, if their internal capabilities to apply highly sophisticated 
analytical methods are limited, RWE is even less valued. Thus HTA evaluations continue to 
rely solely on data from RCTs conducted abroad as the basis for decision-making. While 
some reimbursement schemes for high-cost treatments require applications supported by 
RWE, it has not yet been harnessed and applied by either public- or private-sector 
stakeholders to its full potential.   
Despite these limitations, Latin America has recently seen a surge of interest in RWE, with 
increasing numbers of academics and pharmaceutical companies seeking access to or creating 
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databases and registries to inform HTA submissions and best practices in the healthcare 
sector11. This study presents the sources and uses of RWE in four South-American countries; 
Argentina, Brazil, Chile, and Colombia, with an evaluation of the context-specific challenges 
of data generation and limitations of healthcare system infrastructure. Finally, this study 
considers the implications of this research for future regulation and responsible management 
of RWE in South America. 
2. 0HWKRGV 
We performed a systematic literature review, a database mapping, and a targeted search in the 
grey literature and the websites of governments and relevant public agencies. In addition, we 
developed a series of RWE workshops in Argentina, Brazil, Chile and Colombia where we 
consulted key opinion leaders (KOLs) and validated information previously collected through 
the review. These half-day workshops included three presentations, each followed by a 
discussion session, and were attended by a variety of local stakeholders including 
representatives of the Ministries/Secretaries of Health, public/private HMOs, physicians 
engaged in outcomes research, Statistics Departments, etc. Additional information on the 
workshops can be found in the Supplemental Materials. 
A systematic search was run in the LILACS, MEDLINE and CAB Global Health databases to 
identify sources of RWD and assess the availability and characteristics of RWE in Latin 
America. The search strings included the following terms: µobservational¶ RU µQRQ-
LQWHUYHQWLRQDO¶ RU µUHWURVSHFWLYH¶ RU ¶FRKRUW¶ RU µVXUYH\¶ RU µFURVV VHFWLRQDO¶ RU µGDWDVHW¶ RU
µUHDOZRUOG¶GDWDLQ/DWLQ$PHULFDDQGWKHIRXUFDVHVWXG\FRXQWULHV (see full search string in 
appendix 1). The articles were screened for relevance and they were excluded if the target 
population did not include Argentinian, Brazilian, Chilean and/or Colombian patients; if the 
outcomes were not health-related; and if the study design was a clinical trial, literature review, 
 7 
feasibility analysis or meta-analysis. Reason for exclusion was recorded and, for those 
included, basic information pertaining to the data source used was extracted (name, 
geographic coverage, indication and type of data). The identified sources of RWD were de-
duplicated, and categorised into following three database types: i) administrative databases, ii) 
clinical and patient registries, and iii) national health information systems including 
surveillance.  
KOLs were consulted on the generation and uses of RWE in their respective countries, to 
validate the findings of the literature search, to identify the challenges of incorporating RWE 
into healthcare decision making, and finally to ascertain areas of opportunities. To supplement 
KOL contributions, a targeted literature review was conducted with a focus on health policy 
in Argentina, Brazil, Colombia and Chile. Grey literature, peer-reviewed articles and online 
sources were reviewed from societal, clinical and industry perspective. Search terms for this 
part of the investigation ZHUHWKH IROORZLQJµUHDO-ZRUOGGDWD¶µUHDO-ZRUOGHYLGHQFH¶µHDUO\-
DFFHVVSURJUDPV¶µKHDOWKWHFKQRORJ\DVVHVVPHQWV¶µKHDOWKHFRQRPLFHYDOXDWLRQV¶µH[SDQGHG
DFFHVV SURJUDPV¶ µSHUIRUPDQFH-based risk-shariQJ DJUHHPHQWV¶ µFRPSDVVLRQDWH XVH
SURJUDPV¶ µPDQDJHG-HQWU\DJUHHPHQWV¶ µFRQGLWLRQDO UHLPEXUVHPHQWDJUHHPHQWV¶ µFRYHUDJH
with evidence developPHQW¶DQGµSKDUPDFRYLJLODQFH¶. The authors scanned and categorized 
the contents into three main findings alongside KOL contributions: i) the generation of RWE 
from secondary sources: administrative, registry/clinical and national health information 
systems, ii) the uses of RWE for pharmacovigilance, the monitoring of safety and drug 
utilization, as well as HTA assessments, and iii) the methodological challenges of using RWE 
in practice.  
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3. 5HVXOWV 
  Sources of RWD in Latin America 
Figure 1 presents the PRISMA diagram for the systematic literature review (see Appendix 2 
for additional information). Searches of the LILACS, Medline and CAB global health 
databases retrieved 681 potentially relevant publications from the case-study countries, 
Argentina, Brazil, Chile and Colombia; of which 11 were removed due to duplication. Of the 
remaining 670 studies, 487 were found to be based on relevant sources of RWD. The 
remaining 212 studies were excluded based on study design (n=71), geographic coverage 
(n=135), non-health related outcomes (n=6). 
In the 487 articles screened for abstraction, 407 unique data sources were identified after 
identifying multiple data sources within articles, and de-duplicating databases (n=80). It was 
found that most databases had a population coverage of one hospital or county (n=201), and 
that fewer studies cited data sources with national (n=105) or regional (n=75) coverage. The 
least common were international databases (n=24). Databases were categorised into types, 
with clinical databases (including EMRs) or patient registry databases being the most 
common (n=190), health information systems, including surveillance systems, being the 
second most common (n=101) and finally administrative databases being the scarcest (n=66).  
Most unique databases that were identified in the search covered the Brazilian population 
(n=240), followed by Chile (n=62), Colombia (n=46), Argentina (n=44) and general Latin 
American databases (n=15). The most common studied outcomes were hospital-related 
infections and treatment-related adverse events (pharmacovigilance) (13%), followed by 
cardiovascular diseases (11%), oncology (11%), hospitalizations, surgery and emergency care 
data (8%), maternal and new-born health (7%), TB & other respiratory diseases (5%), and 
STDs including HIV/AIDS (4%).  
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Input from KOLs and targeted literature searches informed definitions of database types as 
follows; administrative databases are classified as data repositories managed at a regional or 
organisational level to capture process indicators from reimbursement, facility or insurance 
data 3. They are used to assess the economic impact of treatments using cost data 11. Secondly, 
health information systems (HIS) are public health surveillance systems characterised by the 
ongoing and systematic monitoring of health events to reduce morbidity and mortality 14. 
They typically monitor key health indicators such as disease prevalence, burden and services 
utilization. Outputs can be used to inform national and provincial ministries of health (MoHs) 
on the needs of healthcare services, and the resulting health statistics are disseminated for 
public access on an aggregated level. Finally, clinical and patient registries consist of 
observational cohort studies for a disease or treatment group, and are typically used for 
understanding the natural history of diseases or monitoring the associated care quality, 
provider performance or cost-effectiveness 3. Error! Reference source not found. shows the 
distribution and types of RWE available in the four South-American case studies, and Error! 
Reference source not found. presents detailed information on four examples per country. For 
example, promising initiatives to create inter-operational national health information systems, 
a selection of condition-specific clinical databases, EMR systems, and finally an example of 
maternal and neonatal databases that typically combine administrative and clinical data, 
though with limited depth.  
 Uses of RWE 
During the desk research phase, we identified  four major uses of RWE globally; i) regulatory 
processes such as marketing authorization, early access schemes and pharmacovigilance, ii) 
HTA decision-making, iii) academic research and iv) healthcare management and financing. 
Error! Reference source not found. shows the current use of RWE in South America, or 
lack thereof, following this taxonomy. We found that, in the countries under study, regulators 
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mainly use RWE for pharmacovigilance purposes. Pharmacovigilance and technovigilance of 
pharmaceutical products and devices are informed by real-world surveillance of adverse 
events (AEs) and treatment patterns. The case studies demonstrate variation between 
FRXQWULHV¶ SKDUPDFRYLJLODQFH UHJXODWLRQV WKDW DSSO\ ZLWK $UJHQWLQD¶V National Drug Food, 
and Medical Technology Administration $10$7 OHJLVODWLRQ UHTXLULQJ ³FRUUHFWLYH
SURFHGXUHV´ DQG &KLOH¶V $1$0(' LQWHUHVW LQ EXLOGLQJ ³VDIHW\ SURILOHV´ XVLQJ 5:( IRU
authorized drugs.  
However, there is limited use of early access schemes for treatments that meet unmet needs or 
to obtain historical comparators for the assessment of orphan indications. While 
pharmaceutical producers in the European Union and United States can apply for early access, 
through Adaptive Pathways (EU) or Breakthrough Therapy (US) designation by agreeing to 
collect post-authorisation RWE in exchange for early authorization of a treatment, this 
strategy is not used in South America where phase III RCTs are deemed to be the gold 
standard for marketing authorization. A rare exception is the occasional approval of 
Compassionate Use Programs, though no RWD collected for secondary use.  
While RCTs are considered the gold standard for HTA submissions, there is a growing 
recognition that observational data is a key tool for budget impact analyses and economic 
evaluations in all South American countries (see Error! Reference source not found.). 
Across South America, payers and producers of biopharma and medical devices are using 
economic and effectiveness RWE to support price and coverage negotiations. However, these 
are the exception and are typically implemented in small populations, by the private sector 
and hardly ever outcomes-based. In Brazil, for instance, while access to RWE is limited by a 
lack of interoperability between regional and organisational systems, there is high utilization 
of RWE amongst HTA agencies. For example, RWE -domestic or international- was included 
in 88.2% of HTA submissions between 2011-2014 15. Elsewhere in Argentina, Colombia and 
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Chile, economic evaluations and cost-minimisation analyses are being conducted to support 
coverage decisions. However, the use of RWE in South America tends to be part of the value 
argumentation of pharmaceutical products, and they are not generally part of the binding 
market access agreements between healthcare payers and pharmaceutical producers.  
Academic institutions in South America use RWE to address transferability to wider 
populations in the region. These, in turn, are used in economic model adaptations for HTA 
submissions. Academic institutions also conduct epidemiological research on mortality, 
incidence and prevalence of diseases based on national surveillance data to inform healthcare 
management and innovation. Institutions across South America are responsible for the 
national or regional disease-specific registries that were started as an individual initiative for 
self-contained research projects. Academic and governmental partnerships have also been set 
up to monitor the performance of the national healthcare system, improve health outcomes 
DQG PRQLWRU RXW RI SRFNHW H[SHQVHV )RU LQVWDQFH &KLOH¶V 0R+ KDV EHJXQ WR GLJLtalise 
GDWDEDVHVV\QFKURQLVHV\VWHPVFROOHFWURXWLQHSRSXODWLRQGDWD$OVR$UJHQWLQD¶V3ODQ1DFHU
is a government-funded auditing programme to monitor quality and allocation of resources in 
clinics treating uninsured women and children. In exchange for funding, clinics across 
Argentina contribute to a surveillance network for maternal and new-born health outcomes.  
 Challenges and opportunities in the collection and consolidation of RWE 
The identification of challenges and opportunities are based on KOL inputs, the proceedings 
of the discussions during the workshops, and insights from the literature pertaining to the 
limitations of the studies reviewed. While they are multiple and diverse, there are some 
common challenges to overcome: as summarized below: 
x Problems with the data. There is a wide variety of available data across all South-
American countries. However, countries face the key challenges of data integrity, quality 
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and security. National variations in data collection, and patient concerns in sharing data 
pose a serious challenge to gathering meaningful insights from data.  
x Gaps in expertise. The KOLs from Brazil, Chile and Colombia pointed out that the 
number of skilled personnel is insufficient to analyse the large volume of data that has, 
and will, become available. To benefit from RWE, all interested parties must address this 
gap and engage in training and capacity building.  
x Lack of confidence in observational research. To capture reliable and transferrable RWE 
for policymaking and HTA decisions, observational research must follow good practices 
as highlighted in the ISPOR Special Task Force report on Real-World Evidence in Health 
Care Decision Making. Studies should be fully transparent, and take steps to resolve 
validity issues of confounding, measurement error, selection bias and missing data 16. The 
aforementioned gaps in expertise and problems with the data foster a conservative attitude 
from the decision makers towards RWE. 
x Trust Issues between users and data holders and among the latter themselves: There is a 
limited, not-always transparent and complex collaboration of various parties (industry, 
academia, hospitals, government, and payers). Data security issues and limited access 
affects the opportunities to analyse the data and utilize the knowledge. In turn, this 
reinforces another difficulty regarding the longitudinal follow-up of patient pathways 
through the different healthcare services. We have not identified any data aggregation 
platforms in the region, which speaks about the impaired cooperation. 
Academics and pharmaceutical industry have advocated for an increased use of RWE 
encouraging other potential users to generate the data and use results. In our case studies, we 
identified some common opportunities to improve the use of RWE: 
x The region has witnessed an extension of healthcare coverage in at least two dimensions 
(bigger population and more diseases/interventions covered) which exerts pressure on 
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healthcare budgets. Thus, there is agreement on the need to monitor results closely, 
particularly those pertaining to high-cost interventions. 
x Data registration is improving in all the countries, with a variety of strategies to address 
specific issues. We have identified initiatives to extend the use of EMRs and improve 
registration (e.g. harmonize coding systems and languages, minimize the use of free text, 
train personnel on coding systems, etc.) and to improve the traceability of patients and 
allow for longitudinal follow-up (e.g. systems integration and central authorities aiming at 
extending data consolidation). 
x There is a rapidly growing number, and maturing of, HTA units in the MoH and 
independent HTA agencies in the region.  
x There is an increase in the various types of HTA institutions and units in South-America, 
and an increasing adoption of pharma-economic guidelines as well as evidence-based 
healthcare policy design, representing a promising prospect for the extended use of RWE 
in the region. 
 
4. &RQFOXVLRQDQG'LVFXVVLRQ 
The literature review indicates that, some patient-level data resources exist in the four 
countries under study. However, the quality of registries and databases vary and are generally 
locally managed without standardized coding and practices between disease groups, hospitals 
and regions.  
The expert contributions reveal that there is occasional use of RWE in HTA submissions, and 
expertise to analyse the supporting data, but at the time of writing RWE is not consistently 
communicated to HTA agencies at a national level. Local HTA agencies leverage RWE in 
their decision-making process in the design of clinical practice guidelines, in systematic 
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reviews of efficacy and safety, as inputs in models (both economic and epidemiological) and 
for resource allocation. The preference for local or international RWE depends on the 
parameter required to be estimated. If the parameter is likely to be influenced by local 
practices, such as resource use or an effectiveness estimate, as opposed to an efficacy 
endpoint, local RWE would be preferred. If the parameter is less likely to be influenced by 
local practices such as the incidence of a rare adverse event, or durability of treatment 
response, evidence from a good quality international source may be admissible, or even 
preferred. HTAs need to balance the need to foster local RWE without overly delaying the 
assessments, which are expedited if international RWE is also considered, after addressing 
transferability issues.   
Opportunities lie in increased capacities for regulation and pharmacovigilance in the form of 
mandatory post-authorisation studies or context-specific RWE guidelines. It is also 
consistently suggested that higher levels of patient involvement may trigger increased levels 
of safety and effectiveness monitoring.  
This research indicates that there are four key policy implications to generating RWE and 
using it to inform decision making; (i) A central authority is required to steward health 
information systems to ensure interoperability and quality guidelines, (ii) Legal and standard 
practice frameworks are also needed for data anonymization and linkage that protect patient 
rights to confidentiality. The FDA does this by sharing only aggregated data beyond local 
networks, but Colombian regulators, for instance, have not put such a barrier in place, which 
raises privacy issues. (iii) Regulation is also required to monitor the transparency and 
reproducibility of results to ensure viable and mutually beneficial models for collaboration. 
(iv) Finally, the allocation of IT resources, training, electronic databases, and storage facilities 
is needed for public healthcare facilities to ensure transferability of routine data collection and 
patient traceability through the entire continuum of healthcare provision. 
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There are limitations to this study, as follows. Country-specific expert opinion was sought for 
each case study, resulting in some inconsistencies in the focus and depth of topics evaluated 
in the countries. Also, since the time of writing (June 2017 - January 2018), there may have 
been updates and changes in the use, laws or regulations of RWD and evidence. Finally, the 
pitfalls of comparing South-American health care systems within the region and to European 
and American health care systems should be highlighted. While no direct country-comparison 
is possible, the funding mechanisms, epidemiological profile and basic structure of South-
American health systems are often fundamentally different to the single-payer systems in 
Europe or the largely private health insurance-reliant US system. In the region under study, 
most countries have a mix of private health care, social security financing and public 
provision for the poor. This means that healthcare is characterised by fragmentation, uneven 
coverage and the associated equity issues. Thus, these comparisons should be interpreted with 
care.  
Recommendations for future research are first to monitor and evaluate the uses of RWE 
produced by the four digital initiatives investigated, SISA (Argentina), DATASUS (Brazil), 
SIPRO (Colombia) and Sidra (Chile). The outcomes of digitalization can be shared with 
healthcare systems in emerging economies in both Latin America and elsewhere, and it is 
recommended that a regional repository of databases to signpost users to freely available data 
is set up to facilitate this. Secondly, it is suggested that future research monitors the uses of 
RWE in HTA decisions, to pinpoint the regulatory bodies, indications and populations that 
include RWE in HTA submissions. Thirdly, the quality of RWD, data analyses and the 
resulting RWE is largely unknown. Future research should examine the transferability, 
reliability and regional variation in routinely collected healthcare databases, and the quality of 
the RWE produced. Finally, future research should to monitor the impact of systematically 
collecting RWD in healthcare settings on the patient experience and health outcomes. The 
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UHVXOWVRIWKLVVWXG\VKRZWKDWDIHHGEDFNPHFKDQLVPVXFKDV$UJHQWLQD¶V3ODQ1DFHUFDQ
dramatically improve patient care by financing well-run clinics that report high quality RWD.  
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Figure 1: Database mapping flow diagram, adapted from Moher D, Liberati A, Tetzlaff 
J, Altman DG, The PRISMA Group (2009). [14] 
 
 Table 1: Summary of health information systems and national health data in four Latin American countries 
National Health Information Systems 
 Argentina - SISA Brazil ± DATASUS Colombia - SISPRO Chile - SIDRA 
Objectives x To improve patient care and 
health system decision-making 
amongst all stakeholders.  
x Optimize information 
management, using a single 
national health information 
system 17.  
x To control payments to public 
and private service providers for 
the SUS1.  
x Collect, process, and 
disseminate healthcare and 
demographic data. 
x Informed decision making, policy 
support, regulatory monitoring and 
service management 18. 
 
x To create a national repository of 
health information and common 
EMRs  
Summary x Quick and reliable sharing of 
information to control validation, 
integrity, security and 
availability. 
x Link human resources and 
streamline services through an 
integrated database and a 
decentralized management 
system. 
x $UJHQWLQD¶VQDWLRQDOKHDOWK
surveillance system, mortality 
statistics and national hospital 
discharge records used to 
monitor history of diseases and 
for health policy planning such 
as assessing the economic impact 
of immunization strategies 19,20 
x Data includes indicators, 
services and products consumed 
as well as estimates of mortality 
and morbidity across specific 
populations. 
x Developed more than 200 
information systems to better 
inform the MoH, plus state and 
municipal secretaries of health. 
x Examples of the uses of 
DATASUS are to access ICD 
codes, utilization of burns 
facilities, and the risk factors for 
TB in remote regions 21,22 
x Data includes patient characteristics, 
health insurance coverage (contributed 
or subsidized), health care facility 
main diagnosis, intervention, length of 
stay and condition when discharged.  
x Colombian MoHs and Social 
Protection register consolidates data 
from the healthcare services using 
ICD-10 codes 23 
x Covers the population that use services 
within Social Security Health System 
24
 
x Data is subject to continuous quality 
control testing 
x SISPRO has been used to analyse 
health care access and causes of death, 
as well as to monitor the rates of 
domestic violence and drug 
interactions 25-27.   
x An integrated information 
system that connects primary 
with the secondary and hospital 
level care 
x Provides longitudinal data 
about care supplied in the 
health system, but also about 
patient outcomes. 
x SIDRA project aims to report 
on the living conditions of 
immigrants, diseases-specific 
hospital resource use and 
incidence rates of different 
diseases 28-30.  
x The hospital discharge database 
is a country-wide 
hospitalizations census.  
x Utilization of services in the 
public (REM) and private 
sector (REMSAS) are available 
from the Department of 
                                                   
1
 The Unified Healthcare System; Sistema Único de Saúde - SUS 
 23 
Statistics in the MoH 31 
Data use 
by third 
party 
x Free public access 
x Access with required registration 
(multiple levels of data 
access/management) 17  
 
x Free access to information 
using National Health Cards. 
x Restricted access to personal 
health records (using a card and 
password). Physicians can access 
examination results, medical 
procedures and medicines 
purchased 32.  
x SISPRO offers patient-level nationwide 
data that is used across the LatAm 
region. Access is free of charge 
following registration process and online 
training for the different modules with 
information on affiliation, diagnosis, 
hospital services and medicines among 
others types of data.  24 
 
x EHRs to be accessible to all 
Chilean healthcare providers 33 
Limitation
s/Challeng
es 
x Not yet fully implemented, still in 
the planning phase 
x Managing the various health 
system resources, interests and 
capacities 
x Surviving management/political 
changes ± key factor for long-term 
projects 
x Prioritising overall benefit rather 
than particular interests 17 
x Longitudinal follow-up of 
individual patients hampered by 
the need to use of probabilistic 
matching in the absence of a 
unique identifier 
x Cannot be used to characterize 
the healthcare system as a whole 
x Limited by incompatible data 
and lack of common definitions 
of healthcare indicators 
x Lack of incentives for routine 
data collection, some patient 
encounters are missed and data 
quality varies 
x The accuracy of diagnoses has been 
questioned.  
x Data tends to be of higher quality for 
high-cost diseases (or procedures) as 
data collection depends on 
reimbursements 34. 
x Overlapping or lack of integration of 
different data sources collecting similar 
or complementary information i.e. 
Registries from the National Cancer 
Institute, the National Health Institute 
,16³&XHQWDGH$OWR&RVWR´HWF 
x Lack resources to unify national 
information systems  
x Compatibility issues from local 
health systems operating own 
information systems pre-SIDRA.  
x Synchronising records, processes 
and information systems is a 
challenge. 
x Supplying resources to cover 
transaction costs associated with 
system migrations is a challenge.  
Disease and condition specific-clinical registries 
 Argentina Brazil Colombia Chile 
 x Immunization registry 
x Blood donor registry 
x Cancer drug bank registry 
x National school health registry 
x Chronic kidney registry 
Cardiovascular registry 
x Hearing aid care registry 
x HIV-AIDS patient management 
system 17 
x National stroke registry 
x HIPERDIA: hypertension and 
diabetes - ensures that 
demographic, epidemiological, 
morbidity and mortality data on 
patients are accessible 
x Stroke prevention in Atrial 
Fibrillation therapy monitor 
x National health and wellness 
survey 
x Kidney transplant registry, Sao 
x Vaccine preventable disease registry 
x Vector transmitted registry 
x Sexually transmitted (incl. HIV-AIDS) 
registry 
x Accident registry 
x Intoxication registry 
x Chronic disease registry.  
x Organ transplant registry 37 
x Tuberculosis surveillance database 38 
x Surveillance system for domestic 
x Immunization registry 
x Blood donor registry 
x Cancer drug bank registry 
x National school health registry 
x Chronic kidney registry 
x Cardiovascular registry 
x Hearing aid care registry 
x HIV-AIDS patient management 
system 17 
x National stroke registry 
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(ReNACer) 35 
 
Paulo 36 
 
violence (SIVIF) 27 
x ³&XHQWDGH$OWR&RVWR´KDVORQJWHUP
information and follow up for Renal 
disease, HIV, and Cancer 
(ReNACer) 35 
Electronic Medical Records (EMR) systems 
 Argentina - Hospital Italiano de 
Buenos Aires 
Brazil - Health National Cards Colombia ±SaludTotal and Sura Chile - Mas Salud Occidente 
Summary x Private sector hospital with 
exemplary health information 
system  
x Sophisticated coding system for 
hospitalizations and prescriptions  
x Facilitates cohort studies 39 
 
x In 2011, the MoH launched a 
strategy to register all Brazilians 
to either a public or private 
healthcare system 40 
x The SUS national health card is 
XVHGWRUHJLVWHUDOOFLWL]HQV¶
diagnoses, prescriptions, and 
hospitalization history. 
x EMRs exist but they are not integrated, 
as they have been developed and 
adopted by different HMOs and health 
care institutions. 
x Large hospitals host clinical and cost 
EMR systems for admitted patients, but 
lack some administrative data 
x Health insurers (such as Salud Total and 
Sura) have implemented EMR systems 
that record administrative outcomes.  
x EMRs rarely combine outcomes.  
x There is a project to unify EMR 
systems for different stakeholders of the 
healthcare system (Historia Clínica 
Electrónica Unificada -HCEU) 
x Among many objectives, Mas 
Salud Occidente aims to manage 
the patient interaction with the 
healthcare network (for e.g. 
waiting lists and referrals) 
x Manages resources such as 
medical supplies and availability 
of beds 33,41 
  
Limitation
s/Challeng
es 
x The sample population at Hospital 
Italiano may not be widely 
representative of the Argentinian 
population because it is a private 
hospital.  
x A 2017 study revealed that in a 
sampled population, only 50% 
were registered and errors 
including incorrect demographic 
data 42 
x Lack of IT infrastructure and 
connectivity limits integration of the 
GDWDDYDLODEOHIURP&RORPELD¶V
healthcare system  
x Lack of training and incentives for 
healthcare professionals to 
maintain pharmacovigilance 
systems  
Example of national condition-specific database for surveillance and informing health policy: Maternal and Neonatal databases 
 Argentina - Plan Nacer  Brazil - SisPreNatal Colombia - ICBF  Chile - FONSA & MoH databases 
Summary x Funding and auditing programme 
to monitor quality and allocation 
of resources in clinics treating 
uninsured women and children.  
x WB and MoH financially 
incentivise healthcare providers. 
x Software developed by 
DATASUS for collecting follow-
up data on more than 3 million 
pregnant women in 5,000 
municipalities in the Unified 
Health System 32. 
x Data freely accessible on the users and 
resource use of childhood health 
promotion and disease prevention 
services, covering early childhood 
nutrition and programs for families and 
communities.  51.  
x National Observatory of the rights 
of the child provides databases on 
key indicators for Chilean 
FKLOGUHQ¶VZHOOEHLQJ52 
x The department of health statistics 
and information also maintains 
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In exchange, a legally binding 
agreement between local and 
national MoHs ensures the supply 
of high quality data.  
x Systematically monitors 
performance in different 
indicators early detection of 
pregnancy, obstetric care, prenatal 
care, immunization coverage, and  
reproductive health 43.  
x Argentina is also part of the 
1,+&'¶VPDWHUQDOQHZ-born 
health registry global network, the 
source of several global studies on 
maternal and neonatal mortality 44-
50
 
x The SUIN database holds 10 years of 
data on health, nutrition, education, 
recreation and sport and protection for 
Colombian children at national and 
municipal levels. 
data on birth statistics, birth 
indicators and birth charts.  
 
Limitation
s/Challeng
es 
Challenging to reach remote areas 
and those that do not register for 
health benefits 43,53. 
x As in many information systems, 
the quality and completion of 
data is very much dependent on 
the person in charge of updating 
the system with the most 
appropriate information.  
x The huge number of 
municipalities (over 5000) in 
Brazil poses a limitation in terms 
of the homogeneity of the data 
quality and completion recorded 
in the system. 
Reports with lots of tables but only 
superficial analysis. 
High maintenance  
EMR: Electronic medical records; ICBF: Institute of Family welfare; LatAm: Latin American; MI: Myocardial Infarction; MoH: Ministry of health; PNEN: Pré-Natal e Nascimento; SIDRA: Sistemas de Informacion de 
la Red Asistencial / Information Systems Healthcare Network; SISA: System of Health Information Systems; SUS: Sistema Único de Saúde; SISPRENATAL: Sistema de Acompanhamento da Gestante; SISPRO: 
Integral Information System of Social Protection; SIDRA; SUIN: Unique Child Information System of the National Family Welfare System; TB: tuberculosis WB: world bank 
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Table 2: Summary of uses of real world evidence in four Latin American countries 
Uses Argentina Brazil Colombia Chile 
Regulatory setting 
and 
pharmacovigilance 
x Rarely used in marketing 
authorization decisions 
x $UJHQWLQD¶VFood, Drug 
and Health Technology 
National Agency 
(ANMAT) manages 
national pharmacovigilance 
systems to detect and 
prevent treatment-related 
AEs. 
x The ANMAT post-
authorization surveillance 
procedure (provision 
8054/10) requires AE and 
quality data to be collected 
during commercialisation, 
and any subsequent 
corrective action to be 
taken54. 
x This enables the early 
detection of AEs during 
normal use to ensure real-
world safety and 
effectiveness54.  
x The Brazilian National 
Health Surveillance 
Agency (ANVISA) 
execute sanitary control of 
the production, marketing 
and use of products and 
services subject to health 
regulation 55. 
x $19,6$¶VWHFKQR-
vigilance system collects 
data on AEs and technical 
complaints related to 
health products in the 
post-marketing phase of a 
product 56. 
x Before granting 
authorisation, ANVISA 
requires an economic 
information report from 
product developers, 
including both 
international and local 
RWE 57.   
x ,19,0$&RORPELD¶V
National food and Drug 
Surveillance Institute 
(formed under the MoH in 
1992) is responsible for 
inspecting the marketing 
and manufacturing of health 
products, implementing 
health standards and 
practices for medical 
approval of import or 
export products58. 
x Regulations are in place to 
oversee the registration, 
marketing, and surveillance 
of production, processing, 
uses, and maintenance of 
medical technologies 59.    
x The National Centre of 
Information on 
Pharmaceuticals and 
pharmacovigilance, part of 
the National Drug 
Regulations Agency 
(ANAMED), is responsible 
for the prevention, detection 
and research of medicinal 
products-related AEs 60 
x RWE is therefore used to 
inform ANAMED of a new 
GUXJ¶VVDIHW\SURILOHSRVW-
commercialisation. 
x This requires the 
collaboration of the Institute 
of Public Health, hospital 
staff (public and private) and 
the manufacturers of devices, 
importers and patients61.   
x  Medical product 
manufacturers are required to 
ensure medical devices meet 
safety and effectiveness 
requirements and maintain 
data to support this through 
post-market surveillance61.    
 
HTA decisions 
(involving HTA 
Agencies and 
manufacturers) 
x Several official or 
academic HTAs exist in 
Argentina (UCEETS, the 
Institute for Clinical 
Effectiveness and Health 
Policy, the HTA Direction 
within ANMAT, the 
IMSSET in UBA and the 
x The National HTA agency 
(CONITEC) was formed 
in 2011 to define the 
criteria for HTA 
submissions to the public 
health system and to 
develop clinical guidelines 
63
.  
x The Colombian HTA 
agency (IETS) was 
established in September 
2012, and is responsible for 
the development and 
appraisal of evidence-based 
clinical guidelines, 
economic evaluations and 
x A 2015 law for funding high 
cost drugs prompted the 
establishment of a 
comprehensive HTA process 
66
  
x In response, economic 
modelling is more frequently 
used, improving the capacity 
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CETSA in iSalud) that 
have used RWE in their 
submissions. However, 
these evaluations were not 
binding until recently 
x Formal HTAs are required 
for health technologies that 
are to be included in the 
compulsory benefits 
packages (PMO or SUR) 
since MoH resolution of 
May 2017. This is expected 
to promote an increase in 
RWE-based economic 
evaluations 62.   
x The pharmaceutical 
industry has funded a 
number of cost-
effectiveness studies using 
RWE, albeit limited.    
x RWD is frequently used in 
CONITEC submissions, 
in particular 
epidemiological, resource 
use and treatment data 
sourced from DATASUS 
64
.  
x Observational studies, 
including chart reviews 
and non-randomized trials 
were used to support 
decisions, and surveys 
were used to identify 
treatment patterns 64.   
x Between 2011-2014, 
88.2% of submissions 
included RWE 15, 
however, most economic 
models were based on 
expert opinion and lacked 
RWE 15.  
x There is a lack of RWE on 
national burden of 
diseases, which impairs 
appraisal decisions 15.  
x To submit technologies 
for reimbursement on the 
µH[SHQVLYHGUXJV¶
producers must submit a 
dossier including RWE 
data (as described above) 
to CONITEC 63. 
budget impact analyses.  
x The IETS is described by 
WKH2(&'DV³RQHRIWKH
most advanced HTA 
DJHQFLHVLQ/DWLQ$PHULFD´
with a transparent and 
collaborate process of 
conducting cost-effective 
analyses 65.  
x Drug costs data from the 
2007 SISMED project, 
which can be freely 
accessed online, are used 
across Latin America in 
modelling exercises and 
budget planning 18.  
to integrate RWE into HTA 
submissions 66.  
x It is expected that the Chilean 
coverage system will trigger 
more RWE to be produced 
and used in HTAs. 
x Economic evidence is 
currently being produced 
mostly with international 
data, though local registries 
are also used to estimate cost 
and resource consumption.  
Academic 
institutions 
multiple uses 
 
 
x The institute for Clinical 
Effectiveness and Health 
Policy (IECS), based at the 
University of Buenos 
Aires, conducts research on 
the clinical, economic and 
social impact of health care 
drugs, practices and 
x DECIT ± CGATS is a 
public-sector 
collaboration between the 
department of science and 
technology and the MoH. 
This public organisation 
collaborates with research 
institutions and public 
x Government managed 
national databases for oral 
health, mental health and 
other disease groups are 
freely accessible to 
researchers.  
x A national cancer 
information system collects 
x Following the legal 
boundaries on access to 
patient data, academic 
institutions may access RWE 
only if conducting research 
that will be contribute to the 
improvement of public health 
and maintains patient 
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services.  
x The IECS has a department 
dedicated to data collection 
system design, database 
quality control and 
statistical analyses, 
demonstrating the 
capability to generate and 
analyse RWE [link].   
x Other academic institutions 
such as the Center for the 
Evaluation of Health 
Technologies (CETSA) 
and the Medical Institute 
for Social Security and 
Health Technology 
Assessment (IMSSET) 
conduct research using 
RWE for scientific 
dissemination as well   
universities to review 
HTA studies.  
x DECIT ± CGATS fosters 
RWE research by 
developing monitoring 
systems for emerging 
technologies and 
guidelines to evaluate 
medical devices 67.   
data on mortality, 
incidence, services and 
inequality at both a local 
and national level, but some 
regions demonstrate under-
coverage and there is a lack 
of peer-reviewed literature 
on existing data 68.  
x Researchers are 
increasingly accessing and 
analysing data both from 
&RORPELD¶VFRPSXOVRU\
registry Sivigila and the 
SISPRO information 
system project 69,70.  
confidentiality 71,72.   
ANAMED: National Drug Regulations Agency; ANMAT: The Food, Drug and Health Technology National Agency of Argentina (Administración Nacional de Medicamentos, Alimentos y Tecnología 
Médica); ANVISA: Brazilian National Health Surveillance Agency; CONITEC: National Committee for Health Technology Incorporation (Comissao Nacional de Incorporaca de Technologias); IECS: 
The (Argentinian) institute for Clinical Effectiveness and Health Policy (Instituto de Efectividad Clinica y Sanitaria); IETS: The (Colombian) agency of health technology assessment (Instituto de 
Evaluación Tecnológica en Salud); PMO: Plan Medico Obligatorio; RedARETS: the Argentine Public Network for HTAs (Red Argentina Pública de Evaluación de Tecnologías Sanitarias); RedETSA: 
HTA Network for the Americas (Red de Evaluación de Tecnologías en Salud para las Américas); SUR: Sistema Único de Reembolso; UCEETS: The HTA Coordination Unit of the Ministry of Health 
(Unidad Coordinadora de Evaluación y Ejecución de Tecnologías en Salud) 
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7. $SSHQGLFHV 
Appendix 1 
Table 3: Workshops Program and Attendees 
Country Argentina Brazil Chile Colombia 
Time and Place Buenos Aires, 18th October 2016 Sao Paulo, 16th September 2016 Santiago de Chile, 20
th
 
October 2016 Bogotá, 24
th
 November 2016 
Opening and first 
Presentation Nahila 
Justo (Karolinska 
Institute, ICON). Q&A 
and open discussion. 
Introduction, Objectives and Agenda.  
First presentation with basic concepts and a situational analysis of the region based on desk research and interviews. 
Title: ³:KDWLV5:(DQGKRZLVLWXVHG":K\LVLWso relevant now? What is the current state of affairs in the Latin-$PHULFDQUHJLRQ"´ 
Second Presentation 
by Michael Drummond 
(University of York). 
Q&A and open 
discussion 
The international perspective with case sWXGLHVDQGNH\OHDUQLQJVZDVLQWURGXFHGLQWKLVSUHVHQWDWLRQWLWOHG³Generation and 
Analysis of RWE: Challenges and Opportunities. The Global Landscape´ 
Third Presentation: 
Country-specific 
perspective introduced 
and discussed by 
country Experts 
Sebastián García Martí introduced 
several examples including Program 
³6XPDU´WKH+HDOWK7HFKQRORJ\
7XWHODJH6\VWHP3$0,¶V&',
Registry and two studies on the 
Impact of Vaccination Impact 
conducted by IECS and the 
³,WDOLDQR´+RVSLWDO 
The local perspective was 
discussed among attendees to 
the workshop and much of the 
interest focused on DATASUS 
and clinical guidelines 
Manuel Espinoza 
Sepulveda presented 
the local perspective 
including uses of RWE 
for HTA purposes, the 
current state of affairs 
of the SIDRA project 
and other relevant 
initiatives. 
Diego Rosselli presented 
local experiences and granular 
information on a good local 
example of accessible 
Colombian RWE (Data from 
Cuenta de Alto Costo) 
Attendees 
Representation from government 
entities such as the Ministries of 
Health (National, CABA, Santa Fé 
and Neuquén), the Superintendence 
of Health Services, and ANMAT; 
from public and private HMOs 
(PAMI, IOMA, Medife, Osplad, 
OSDE, Medicus, Galeano, Omint, 
OSPIM); from education and 
research (CETSA Isalud, IECS, 
OBIME Maimónides); and members 
of professional associations 
(CAEMe, CENEXA, INC)  
Academia, physicians,  
healthcare providers and other 
stakeholders (ICESP, Hospital 
Infantil Darcy Vargas, Hospital 
Santa Paula, Sao Paulo 
Secretary of Health, UNIMED, 
Instituto de Saúde, Universidade 
Estadual Paulista Júlio de 
Mesquita Filho, Magara, 
PLANSERV, Kantar Health, BSI,  
Representatives of the 
National Health Fund 
(FONASA), private 
insurers (ISAPRES), 
Ministry of Health. 
Academia and health 
providers either public 
or private. 
Representation from 
government entities like 
Ministry of health, National 
Cancer Institute, National 
Health Institute, the Colombian 
Association of Hospitals and 
Clinics (ACHC), HMOs in 
Subsidized and Contributive 
regime (Gestarsalud, Sanitas 
EPS), Audifarma Research 
Group (logistic operator) and 
Javeriana University 
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Appendix 2 
 
Table 4: Database mapping search string 
CAB Global Health Database Guide 1973 to 2017 Week 48 
Ovid Medline (R) Epub ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE 
(R) Daily, Ovid MEDLINE and Versions(R) 
Search conducted December 12, 2017 
# Search Search term Number of hits 
1   (national or nationally).ti,ab. 578770 
2   population level.ti,ab. 19712 
3   
(multinational or multinationally or multi-national or 
multi-countr$3 or multicountr$3).ti,ab. 11145 
4   (regional or regionally).ti,ab. 276742 
5   
 (country-wide level or country level or country 
population).tw. 3001 
6    nationally representative sample.tw. 10277 
7    regionally representative sample.tw. 30 
8    population-based.ti,ab. 155441 
9    Global population$1.tw. 3222 
10    Continental Population$1.tw. 281 
11 General/population  or/1-10 987873 
12    database$1.ti,ab. 404583 
13    (register$1 or registry or registries).ti,ab. 191602 
14    (real world or real life or evidence based data).ti,ab. 45907 
15    (national program$1 or health program$1).mp. 66624 
16    claim$1.ti,ab. 74333 
17   
 (electronic medical record$1 or medical record$1 or 
health record$1).ti,ab. 122789 
18   
 *Population Surveillance/ or (Health surveillance or 
population surveillance).ti,ab. 26694 
19    *Information Systems/ or Information System$1.ti,ab. 46090 
20   
 *Health Surveys/ or exp Health Care Surveys/ or 
(health adj2 survery$1).ti,ab. 45213 
21   
 *Health maintenance organization/ or Health 
maintenance organi?ation$1.ti,ab. 13616 
22    dataset.ti,ab. 50380 
23 Data sources  or/12-22 995158 
24    11 and 23 184126 
25    observational.ti,ab. or Observational Study/ 191662 
26    non interventional.ti,ab. 2171 
27    *retrospective studies/ or retrospective.ti,ab. 505817 
28    *prosepctive studies/ or prospective.ti,ab. 601885 
29    *cohort studies/ or cohort.ti,ab. 543447 
 31 
30    *cross-sectional study/ or cross-sectional.ti,ab. 381490 
31    *longitudinal study/ or longitudinal.ti,ab. 252406 
32 Study design  or/25-31 1996308 
33    24 and 32 59301 
34    cost$1.ti,ab. 572023 
35    (quality of life or QoL or HRQoL).ti,ab. 269257 
36   
 (treatment$1 or prescription$1 or prescribed or 
drug$1 or medicine$1 or medication$1).ti,ab. 6340663 
37    *incidence/ or incidence.ti. 119848 
38    *prevalence/ or prevalence.ti. 172441 
39    *morbidity/ or morbidity.ti. 38392 
40    *mortality/ or (mortality or death or dead or die).ti. 279377 
41    (life year$1 or survival).ti,ab. 954402 
42    comorbidit$3.ti,ab. 110699 
43    (adverse event$1 or safety).ti,ab. 624218 
44    (hospitali?ation$1 or admission$1).ti,ab. 364490 
45    risk factor$1.ti,ab. 662739 
46    patient outcome assessment$1.ti,ab. 21 
47    generic measure$1.ti,ab. 786 
48    effectiveness.ti,ab. 461426 
49 Data types   or/34-48 8793013 
50    33 and 49 42667 
51    crossover procedure/ 0 
52    single blind procedure/ 0 
53    randomized controlled trial/ 543455 
54    double blind procedure/ 0 
55    randomi?ed controlled trial.ti,ab. 96619 
56    randomi?ed clinical trial.ti,ab. 31004 
57    random$.ti. 229593 
58    (crossover* or cross over*).ti. 14837 
59    (((doubl* or singl*) adj blind*) or clinical trial).ti. 84824 
60   
 (case report or news or comment* or letter or rat or 
rats or mouse or mice).ti. 1893459 
61 
Irrelevant 
publication types  or/51-60 2568964 
62    50 not 61 41783 
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63   
 limit 62 to (book or book series or conference abstract 
or conference paper or conference proceeding or 
"conference review" or editorial or erratum or letter or 
note or "review" or trade journal or addresses or 
autobiography or bibliography or biography or case 
reports or clinical conference or clinical trial, all or 
clinical trial, phase i or clinical trial, phase ii or clinical 
trial, phase iii or clinical trial, phase iv or clinical trial 
or comment or congresses or consensus development 
conference or consensus development conference, nih 
or controlled clinical trial or dictionary or directory or 
duplicate publication or festschrift or guideline or 
historical article or in vitro or interactive tutorial or 
interview or lectures or legal cases or legislation or 
meta analysis or news or newspaper article or patient 
education handout or periodical index or portraits or 
practice guideline or pragmatic clinical trial or 
published erratum or randomized controlled trial or 
"research support, american recovery and reinvestment 
act" or research support, nih, extramural or research 
support, nih, intramural or research support, non us 
gov't or research support, us gov't, non phs or research 
support, us gov't, phs or retracted publication or 
"retraction of publication" or "scientific integrity 
review" or systematic reviews or technical report or 
twin study or validation studies or video-audio media 
or webcasts) [Limit not valid in Books@Ovid,Global 
Health,Ovid MEDLINE(R),Ovid MEDLINE(R) Daily 
Update,Ovid MEDLINE(R) In-Process,Ovid 
MEDLINE(R) Publisher; records were retained] 
19832 
64 
Excluding 
irrelevant 
publication types 
 62 not 63 21951 
65 limit to humans 
 limit 64 to humans [Limit not valid in 
Books@Ovid,Global Health; records were retained] 17471 
66 
limit to latin 
america or case 
study countries 
 (Latin americ$ or south america$ or argentin$ or 
bra$il$ or colombia$ or chile$).ti,ab. 106924 
67    65 and 66 121 
68 
Studies published 
from 2007 
onwards 
 limit 67 to yr="2007 -Current" 114 
69 After de-duplication  remove duplicates from 68 96 
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Table 5: Databases by geographic region, scope and database type 
 
 
Data sources by geographic region  Database coverage (n) 
Country n (%) International National  Regional  Local Not 
reported 
Argentina 44 11% 7 9 5 23 0 
Brazil 240 59% 3 57 57 123 0 
Chile 62 15% 2 21 4 35 0 
Colombia 46 11% 0 16 9 20 1 
Latin America (non-
specific) 
15 4% 12 2 0 0 1 
Data sources by database type  Database coverage (n) 
Database type  n (%) International National  Regional  Local Not 
reported 
Administrative 66 14% 2 11 5 47 1 
Clinical / registry data  190 43% 11 16 26 136 1 
National Health 
Information & 
surveillance Systems 
151 42% 
11 78 44 18 0 
Total included articles 46 100% 24 105 75 201 2 
 
